Механизмы повреждающего действия лекарств на плод и значение фармакогенетики для безопасности лекарств у беременных
https://doi.org/10.1234/XXXX-XXXX-2015-12-3-10
Аннотация
В статье описаны предполагаемые механизмы повреждающего действия лекарственных средств на плод и приведены данные о возможной роли генетических особенностей матери и плода в реализации этих воздействий.
Ключевые слова
беременность,
плод,
фармакогенетика,
побочные эффекты лекарств,
pregnancy,
fetus,
pharmacogenetics,
adverse drug reactions
Об авторах
К. А. Загородникова
ГБОУ ВПО СЗГМУ им. И.И.Мечникова; Северо-западный медицинский центр безопасности лекарств при беременности и лактации
Россия
Россия
А. Т. Бурбелло
ГБОУ ВПО СЗГМУ им. И.И.Мечникова; Северо-западный медицинский центр безопасности лекарств при беременности и лактации
Россия
Россия
М. В. Покладова
ГБОУ ВПО СЗГМУ им. И.И.Мечникова; Северо-западный медицинский центр безопасности лекарств при беременности и лактации
Россия
Россия
Список литературы
1. Загородникова К.А., Бурбелло А.Т., Покладова М.В. Безопасность лекарств и фармаконадзор у беременных - от “талидомидовой трагедии” до наших дней // Ремедиум.- 2012.- № 8.- С. 15-22.
2. Российский статистический ежегодник. 2014: стат.сб. Москва: , 2014.
3. Adam M. The all-or-none phenomenon revisited // Birth defects research. Part A, Clinical and molecular teratology. - 2012. - Т.94 №8. - С.664-9.
4. Ahmadimoghaddam D. идр. Synchronized activity of organic cation transporter 3 (Oct3/Slc22a3) and multidrug and toxin extrusion 1 (Mate1/Slc47a1) transporter in transplacental passage of MPP+ in rat. // Toxicological sciences : an official journal of the Society of Toxicology. -2012. -Т. 128. № 2. -С. 471-81.
5. Ajslev T.A., Sorensen T.I.A., Jess T. Maternal inflammatory bowel disease and offspring body size: a prospective cohort study. // Inflammatory bowel diseases. -2012. -Т. 18. № 4.-С. 709-17.
6. BliekB.J.B. и др. Maternal medication use, carriership of the ABCB1 3435C > T polymorphism and the risk of a child with cleft lip with or without cleft palate. // American journal of medical genetics. Part A. -2009. -Т. 149A. № 10. -С. 2088-92.
7. Botto L.D., Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. // American journal of epidemiology. -2000. -Т. 151. № 9.-С. 862-77.
8. Candiotti K.A. идр. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? // Anesthesiology. -2005. -Т. 102. № 3. -С. 543-9.
9. DaudA.N.A. и др. Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins. // Pharmacogenomics. -2014. -Т. 15. № 7.-С. 1029-41.
10. Dreier J.W., Andersen A.-M.N., Berg-Beckhoff G. Systematic review and meta-analyses: fever in pregnancy and health impacts in the offspring. // Pediatrics. -2014. -Т. 133. № 3. -С. e674-88.
11. Fejzo M.S., MacGibbon K., Mullin P. Intestinal obstruction is a rare complication of ondansetron exposure in hyperemesis gravidarum. // Reproductive toxicology (Elmsford, N.Y.). -2015.
12. Gabbay-Benziv R. идр. Birth defects in pregestational diabetes: Defect range, glycemic threshold and pathogenesis. // World journal of diabetes. -2015. -Т. 6. № 3. -С. 481-8.
13. Gelder M.M.H.J. van идр. Teratogenic mechanisms of medical drugs. // Human reproduction update. -Т. 16. № 4. -С. 378-94.
14. Gordeeva L.A. идр. Association GSTT1, GSTM1 and GSTP1 (Ile105Val) genetic polymorphisms in mothers with risk of congenital malformations in their children in Western Siberia: a case-control study. // Prenatal diagnosis. -2013. -Т. 33. № 11. -С. 1095-101.
15. Haas D. Pharmacogenetics and individualizing drug treatment during pregnancy // Pharmacogenomics.- 2014. -Т. 15. -С. 69-78.
16. Haas D.M. идр. A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic. // The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. -2012. -Т. 25. № 4.-С. 419-23.
17. Haas D.M. идр. The impact of glucocorticoid polymorphisms on markers of neonatal respiratory disease after antenatal betamethasone administration. // American journal of obstetrics and gynecology. -2013.-Т. 208. № 3. -С. 215.e1-6.
18. HemauerS.J. и др. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. // Biochemical pharmacology. -2010. -Т. 79. № 6. -С. 921-5.
19. Herbst A.L., Ulfelder H., Poskanzer D.C. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. // The New England journal of medicine. -1971. -Т. 284. № 15. -С. 878-81.
20. Klaassen C.D., Aleksunes L.M. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. // Pharmacological reviews. -2010. -Т. 62. № 1.-С. 1-96.
21. Kobayashi D. идр. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. // Drug metabolism and disposition: the biological fate of chemicals. -2005. -Т. 33. № 1. -С. 94-101.
22. Koepsell H., Endou H. The SLC22 drug transporter family. // Pflügers Archiv : European journal of physiology. -2004. -Т. 447. № 5.-С. 666-76.
23. Koren G. Pharmacokinetics in pregnancy; clinical significance. // Journal of population therapeutics and clinical pharmacology = Journal de la thérapeutique des populations et de la pharamcologie clinique. -2011. Т. -18. № 3. -С. e523-7.
24. Koren G., Bozzo P. Cost effectiveness of teratology counseling - the Motherisk experience. // Journal of population therapeutics and clinical pharmacology = Journal de la thérapeutique des populations et de la pharamcologieclinique.- 2014. -Т. 21. № 2. С.- e266-70.
25. Landau R. идр. Arg16 homozygosity of the beta2-adrenergic receptor improves the outcome after beta2-agonist tocolysis for preterm labor. // Clinical pharmacology and therapeutics. -2005. -Т. 78. № 6. -С. 656-63.
26. LankasG.R. и др. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. // Reproductive toxicology (Elmsford, N.Y.). -Т. 12. № 4. -С. 457-63.
27. Larsen W. Human embryology. Philadelphia: Churchill Livingstone. - 2001. -Вып. 3rd editio.
28. Lehmann A.S. идр. Pharmacogenetic predictors of nausea and vomiting of pregnancy severity and response to antiemetic therapy: a pilot study. // BMC pregnancy and childbirth. -2013. -Т. 13. -С. 132.
29. Linden I.J.M. van der идр. The methionine synthase reductase 66A>G polymorphism is a maternal risk factor for spina bifida. // Journal of molecular medicine (Berlin, Germany). -2006. -Т. 84. № 12. -С. 1047-54.
30. Lupattelli A. идр. Medication use in pregnancy: a cross-sectional, multinational web-based study. // BMJ open. -2014. -Т. 4. № 2. -С. e004365.
31. Luteijn J., Brown M., Dolk H. Influenza and congenital anomalies: a systematic review and meta-analysis. // Human reproduction. - 2014. - Т. 29 № 4. - С. 809-23.
32. Madadi P. идр. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. // Clinical pharmacology and therapeutics. -2009. -Т. 85. № 1.-С. 31-5.
33. Mazor-Dray E. идр. Maternal urinary tract infection: is it independently associated with adverse pregnancy outcome? // Journal of Maternal-Fetal and Neonatal Medicine. -2009. -Т. 22. № 2. -С. 124-128.
34. Meyer zuSchwabedissen H.E. идр. Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. // Drug metabolism and disposition: the biological fate of chemicals. -2005. -Т. 33. № 7. -С. 896-904.
35. Ni Z., Mao Q. ATP-binding cassette efflux transporters in human placenta. // Current pharmaceutical biotechnology. -2011.-Т. 12. № 4. -С. 674-85.
36. Obermann-Borst S.A. идр. General maternal medication use, folic acid, the MDR1 C3435T polymorphism, and the risk of a child with a congenital heart defect. // American journal of obstetrics and gynecology. -2011. -Т. 204. № 3. -С. 236.e1-8.
37. Oretti C. идр. Glutathione-S-transferase-P1 I105V polymorphism and response to antenatal betamethasone in the prevention of respiratory distress syndrome. // European journal of clinical pharmacology. -2009.-Т. 65. № 5.-С. 483-91.
38. Parle-McDermott A. идр. Confirmation of the R653Q polymorphism of the trifunctional C1-synthase enzyme as a maternal risk for neural tube defects in the Irish population. // European journal of human genetics : EJHG.- 2006. -Т. 14. № 6.-С. 768-72.
39. Rahi M. идр. Placental transfer of quetiapine in relation to P-glycoprotein activity. // Journal of psychopharmacology (Oxford, England). -2007. -Т. 21. № 7. -С. 751-6.
40. Rahi M. идр. Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placenta. // Human & experimental toxicology. -2008. -Т. 27. № 1.-С. 65-71.
41. Rawles L.A., Acuna D., Erickson R.P. The role of multiple drug resistance proteins in fetal and/or placental protection against teratogen-induced orofacial clefting. // Molecular reproduction and development. -2007.-Т. 74. № 11.-С. 1483-9.
42. Schaefer C. Drug safety in pregnancy: utopia or achievable prospect? Risk information, risk research and advocacy in Teratology Information Services. // Congenital anomalies. -2011. -Т. 51. № 1.-С. 6-11.
43. Shapira S., Dolan S. Genetic risks to the mother and the infant: assessment, counseling, and management. // Maternal and child health journal. - 2006. - T.10 №5. - C. S143-6.
44. Shepard T.H., Lemire R.J. Catalog of teratogenic agents.11th ed. // The John Hopkins University Press, Baltimore. - 2004. - 487 C.
45. Staud F., Cerveny L., Ceckova M. Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. // Journal of drug targeting.- 2012.-Т. 20. № 9.-С. 736-63.
46. Stevens A. идр. Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype. // The Journal of clinical endocrinology and metabolism. -2004.-Т. 89. № 2.-С. 892-7.
47. Teh L.K., Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. // Drug metabolism and pharmacokinetics.- 2012.-Т. 27. № 1.-С. 55-67.
48. Tertti K. идр. Transfer of repaglinide in the dually perfused human placenta and the role of organic anion transporting polypeptides (OATPs). // European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. -2011.-Т. 44. № 3.-С. 181-6.
49. Ugele B. идр. Characterization and identification of steroid sulfate transporters of human placenta. // American journal of physiology. Endocrinology and metabolism. -2003.- Т. 284. № 2.- С. E390-8.
Рецензия
Для цитирования:
Загородникова К.А., Бурбелло А.Т., Покладова М.В. Механизмы повреждающего действия лекарств на плод и значение фармакогенетики для безопасности лекарств у беременных. Медицинская генетика. 2015;14(12):3-10. https://doi.org/10.1234/XXXX-XXXX-2015-12-3-10
For citation:
Zagorodnikova K.A., Burbello A.T., Pokladova M.V. Mechanisms of fetal adverse drug effects and importance of pharmacogenetics for safe medication use in pregnancy. Medical Genetics. 2015;14(12):3-10. (In Russ.) https://doi.org/10.1234/XXXX-XXXX-2015-12-3-10
Просмотров: 448
Послать статью по эл. почте 